An A3 Executive Reference (2 pages) Japan rewards programs that are sequenced, evidenced, and locally socialized. […]
Cracking Japan’s Pharma Ecosystem: Field Notes from ~20 Years in the Trenches Japan rewards sequencing, proof, […]
As mRNA biotechnology matures, few firms have demonstrated a shift as dynamic as Moderna. Widely recognised […]
In the mid-1990s, Japan was not merely participating in the global pharmaceutical industry—it was shaping it. […]
Just now, AstraZeneca is making headlines with a $5.3 billion AI research partnership with China’s […]
Japan’s IVD sector remains highly structured and closely governed, benefiting from a mature healthcare infrastructure and […]
Some of Japan’s most forward-thinking minds gathered to scrutinise Japan’s biobank conundrum at Shonan iPark. In […]
Navigating Japan’s life sciences sector successfully hinges on more than just excellent science or a meticulously […]
It started with a headline I read on the train to kendo practice. AstraZeneca is setting […]
Is Japan’s Drug Pricing Squeeze Finally Loosening? Japan has long been a high-pressure pricing environment for […]